Fig. 2.
Kaplan-Meier estimates of the distributions of survival from day of study entry, by disease onset, based on 211 patients with centrally confirmed diagnoses of non-M3 AML. Tickmarks indicate censored data.
Kaplan-Meier estimates of the distributions of survival from day of study entry, by disease onset, based on 211 patients with centrally confirmed diagnoses of non-M3 AML. Tickmarks indicate censored data.
